|
Coronary Artery Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, the correlation between COX-2 expression and MPA levels, and the association of COX-2 expression with CAD risk were assessed.
|
31700919 |
2019 |
|
Coronary Artery Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
All NSAIDs, not just selective Cox 2 inhibitors, have associated with them different degrees of cardiac risk; therefore, NSAIDs should be avoided when treating patients with underlying CAD.
|
30345832 |
2018 |
|
Coronary Artery Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cyclooxygenase-2 (COX-2), a key synthase in prostaglandin pathways, displays high density in atherosclerotic lesions and promotes early atherosclerosis in CAD progression.
|
28194409 |
2017 |
|
Coronary Artery Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cyclooxygenase-2 inhibitors (coxibs) are characterized by multiple molecular off-target effects and increased coronary artery disease (CAD) risk.
|
28860667 |
2017 |
|
Coronary Artery Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis suggests that PTGS2 -765G>C is associated with a decreased risk of CAD.
|
24446343 |
2014 |
|
Coronary Artery Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that COX-2 rs20417 polymorphism may contribute to CAD development, especially in Asians.
|
24513487 |
2014 |
|
Coronary Artery Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Moreover, there was a synergistic effect between smoking and the PTGS2 polymorphism and the occurrence of CAD (interaction p=0.009).
|
21091235 |
2011 |
|
Coronary Artery Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Cox-2 gene polymorphism and IL-6 levels in coronary artery disease.
|
21574137 |
2011 |
|
Coronary Artery Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Functional promoter polymorphism of cyclooxygenase-2 modulates the inflammatory response in stable coronary heart disease.
|
20332714 |
2010 |
|
Coronary Artery Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A secondary aim was to replicate the interaction of PTGS2 rs20417 (-765G to C) with aspirin use on coronary heart disease risk observed in the Atherosclerosis Risk in Communities Study (ARIC).
|
19046748 |
2009 |
|
Coronary Artery Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The objective was to assess the relationship of COX-2 G-765C and CAD and ischemic stroke, using a meta-analysis.
|
19631939 |
2009 |
|
Coronary Artery Disease
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
COX-2 CC homozygotes (variant allele), were more common, while EP2 GG homozygotes (wild-type) were less common in ACS (p = 0.03 and p = 0.017) than in the sCAD group.
|
18989535 |
2008 |
|
Coronary Artery Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
COX-2 CC homozygotes (variant allele), were more common, while EP2 GG homozygotes (wild-type) were less common in ACS (p = 0.03 and p = 0.017) than in the sCAD group.
|
18989535 |
2008 |
|
Coronary Artery Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
COX-2 gene promoter polymorphism and coronary artery disease in middle-aged men: the Helsinki sudden death study.
|
18385811 |
2008 |
|
Coronary Artery Disease
|
0.400 |
Biomarker
|
disease |
CTD_human |
The addition of selective COX-2 inhibition with rofecoxib did not appear to have any favorable or adverse effects on endothelial dysfunction or vascular inflammation in patients with CAD using concomitant low-dose aspirin.
|
14642682 |
2003 |